MEA Active Pharmaceutical Ingredients Market

MEA Active Pharmaceutical Ingredients Market Size (2023 to 2028)

The size of the active pharmaceutical ingredients market is forecasted to be growing at a healthy rate during the forecast period.

The active pharmaceutical ingredients market in the MEA region is one of the lucrative and fast-growing markets in the domain of the pharma industry. The Middle East and African region are an untapped part of the global API market. The main drivers for the market are the rising geriatric population; in the coming ten years, Africa has become the second most populous and aged country globally. In addition to that, due to the fast development happening in the countries of Africa and ME, there is an increased life expectancy in some of the countries of this region. It is increasing non-transmissible chronic diseases like cardiovascular disorders, obesity, and diabetes. Apart from these aspects, the MEA region diversifies the scope for installing the APIs manufacturing units in the region.

As the countries in the region of Africa are experiencing mass urbanization, there is increased spending on health. The Govt of developed nations in these regions like Saudi and other nations import branded products contributing a lot to the APIs market. Govt policies towards the manufacturers of APIs are helping the market to be on a growth trajectory. Due to the availability of cheap labor, manufacturers are looking at these countries to install units over here.

Many of the African countries are poor, and the people in these countries cannot afford to purchase branded medicines with effective APIs. So, there is a huge reliance on Generic drugs, which inhibits the APIs market in the region. Govt protocols, these countries follow borrowed protocols of international bodies, which are barring the API manufacturers in getting regulatory approvals. Hence it is restraining the top global players from creating a market in this region. Due to the increased generics, every country in this region is trying to restrict the global companies' imports and stress them to localize in their countries. This is a big restraint to the companies in the creation of a huge market.

Impact of COVID-19 on the MEA API Market:

Covid-19 has impacted the region in both ways; during the first wave, there was an increased case of COVID-19 in the countries of this region. This escalated the demand for APIs from different countries, and the region has witnessed a supply chain disruption as it is importing APIs from china majorly. In the aftermath of the pandemic, countries of this region are procuring life-saving medicines in large quantities because they are importing APIs and installing APIs manufacturing hubs on a large scale triggering the growth of the APIs market in the region.

This research report on the Middle East and Africa active pharmaceutical ingredients market has been segmented and sub-segmented into the following categories.

By Type of Manufacturing Process:

• Captive Manufacturing
• Contract Manufacturing

By Type of Synthesis:

• Synthetic
• Biotech

By API Formulation:

• Generic API
• Innovative API

By Application:

• Cardiovascular Diseases
• Oncology
• Neurological Disorders
• Orthopedic Disorders
• Respiratory
• Gastrointestinal Disorders
• Urology
• Others

By Molecule:

• Large Molecule
• Small Molecule

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

In the Middle East and Africa region, there are large disparities in terms of wealth, development, science and technology, and health care. In the middle east countries like Saudi Arabia, Israel, UAE, and other developed countries, health care is very much consolidated, and they spend a lot on health care. Due to the advanced sci & tech development, import APIs for producing branded drugs with world-class facilities. Over 85% of the products are imported from reputed players.

In the case of African nations, the demand for APIs is increasing year on year; when coming to South Africa, the country is incentivizing the APIs production units faster. Nigeria is one of the top pharmaceutical manufacturing countries globally, with a notable share experiencing an average CAGR of 6%. The African region is expected to grow to USD 85 billion by the end of 2025. North African region countries like Tunisia, Morocco, and Egypt also experience notable growth in APIs Industry.

KEY MARKET PLAYERS:

AbbVie Inc., AstraZeneca, Aurobindo Pharma Ltd., BASF, Bayer AG, Boehringer Ingelheim, Dr. Reddy's Laboratories, F. Hoffmann-La Roche, GlaxoSmithKline plc, Lonza Group, Lupin Limited, Merck & Co., Inc., Mylan NV, Novartis International AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. are some of the noteworthy companies in the MEA active pharmaceutical ingredients market.